Applied Genetic Technologies EBIT

Applied Genetic Technologies (AGTC) currently reports a EBIT of $-52M as of September 2022. That compares with $-60M in the prior-year period — up 13.7% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Applied Genetic Technologies's EBIT history and peer comparisons.

Applied Genetic Technologies's EBIT increased from $-60M to $-52M — a 13.7% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Applied Genetic Technologies's EBIT of $-52M is lower than the Healthcare sector average of $23B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Applied Genetic Technologies reported $-52M in EBIT as of September 2022. That compares with $-60M in the prior-year period — up 13.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-52M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Applied Genetic Technologies, and consider following AGTC for alerts when major investors trade the stock.